Investigació Aplicada en Malalties Respiratòries


  • Friday, 04/27/2018

    2 IAMR Group Research Projects have been awarded by SEPAR in the 2017 Call for Grant Applications

    The SEPAR 2017 Grants of Fundació Respira (Spanish Lung Foundation) will invest around 600.000 euros in research

     The IAMR research team has been successful in the 2017 call for the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) - Fundació Respira grants ( Miquel Ferrer and Enric Barbeta obtained funding to carry out their research projects in the field of respiratory diseases.

    Dr. Miquel Ferrer obtained a SEPAR 2017 grant for his project Reducing the duration of antibiotic treatment of community-acquired pneumonia with high risk class and initially appropriate response. A randomised clinical trial. The aims for this trial are: 1) To assess the efficacy of 5-day antibiotic treatment compared to the usual duration of more than 7 days, in a non-inferiority design, in terms of “mortality, hospital readmission or reinitiating of antibiotic treatment at 30 days”, in a cohort of patients with community-acquired pneumonia with a PSI risk class IV-V who present an initially adequate response to treatment (clinical stability within the first 4 days of treatment alter admission); 2) To assess the efficacy of 5-day antibiotic treatment compared to the usual duration of more than 7 days on hospital lenght of stay and antibiotic-free days at 30 days and; 3) To investigate the occurrence of adverse events related to the use of study antibiotics 

    Enric Barbeta obtained a SEPAR 2017 grant for his project Driving Pressure and Inflammatation in Acute Respiratory Distress Syndrome. The aim of this project is to analyze the association between driving pressure and pulmonary and systemic inflammation as well as the severity of multiorgan failure in patients with ARDS undergoing invasive mechanical ventilation.

    SEPAR-Fundació Respira awards a number of grants each year with the aim of encouraging research in the field of respiratory disease. 


  • Tuesday, 12/12/2017

    A new combination of antibiotics allows treating 60% of hospital-acquired pneumonia

    Prof. Antoni Torres Martí

    A study published in the journal The Lancet Infectious Diseases shows the ability of a new antibiotic (ceftazimida-avibactam) to treat hospital-acquired pneumonia, including ventilation-associated pneumonia. It has similar efficacy to one of the most used type of antibiotics in the treatment of this infection, carbapenems, but has the advantage of overcoming problems derived from its administration, such as the resistance of certain bacteria.   Dr. Antoni Torres, Head of the Respiratory Intensive Surveillance Unit (UVIR) of the Hospital Clínic and head of the IDIBAPS team on Applied research in infectious respiratory diseases, is the principal investigator of the study and first author of the article. 


  • Wednesday, 11/08/2017

    A blood test allows the identification of patients with pneumonia with a higher associated mortality

    The work has been published by the journal EBioMedicine.

     A multidisciplinary team of researchers, led by the Hospital Clínic de Barcelona-IDIBAPS, the La Fe Hospital in Valencia and the Valladolid University Clinic Hospital, has identified an immunological subtype of Pneumonia Acquired in the Community (CAP) that is associated to a greater mortality. It is a community pneumonia with low blood lymphocytes and has twice the risk of mortality. Patients with this subtype are easy to identify using a simple hemogram, the most common blood test available in all hospitals. The work has been published by the journal EBioMedicine.


More news

Subscribe to news